Progyny, Inc. (PGNY)
NASDAQ: PGNY · Real-Time Price · USD
18.38
-0.03 (-0.16%)
At close: Apr 28, 2026, 4:00 PM EDT
18.30
-0.08 (-0.44%)
After-hours: Apr 28, 2026, 7:50 PM EDT

Company Description

Progyny, Inc., a benefits management company, provides fertility, family building, and women’s health benefits solutions in the United States.

It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists.

The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions.

In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services.

The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Progyny, Inc.
Progyny logo
Country United States
Founded 2008
IPO Date Oct 25, 2019
Industry Healthcare Plans
Sector Healthcare
Employees 856
CEO Peter Anevski

Contact Details

Address:
1359 Broadway
New York, New York 10018
United States
Phone 212 888 3124
Website progyny.com

Stock Details

Ticker Symbol PGNY
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $13.00
CIK Code 0001551306
CUSIP Number 74340E103
ISIN Number US74340E1038
Employer ID 27-2220139
SIC Code 8090

Key Executives

Name Position
David J. Schlanger J.D. Executive Chairman
Melissa B. Cummings Chief Operating Officer
Allison Swartz Executive Vice President, General Counsel and Secretary
Geoffrey Clapp Chief Product Officer
Steven Leist Chief Technology Officer
James Hart Vice President of Investor Relations
Risa Fisher Chief Marketing Officer
Cassandra Pratt Chief Human Resources Officer
Julie Stadlbauer Chief Business Development Officer
Janet Choi M.D. Member of the Medical Advisory Board and Chief Medical Officer

Latest SEC Filings

Date Type Title
Apr 10, 2026 ARS Filing
Apr 10, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 10, 2026 DEF 14A Other definitive proxy statements
Mar 31, 2026 PRE 14A Other preliminary proxy statements
Mar 27, 2026 SCHEDULE 13G/A Filing
Mar 13, 2026 8-K Current Report
Mar 4, 2026 144 Filing
Mar 3, 2026 144 Filing
Mar 2, 2026 144 Filing
Feb 27, 2026 S-8 Securities to be offered to employees in employee benefit plans